Glycosmedia

Diabetes News Service

Privacy & Cookies: This site uses cookies. By continuing to use this website, you agree to their use.
To find out more, including how to control cookies, see here: Cookies Policy
  • News
  • Archive
  • Categories & Tags
  • Journal Watch
  • Updates
  • Education
  • Reviews
  • About us ▼
    • About Glycosmedia
    • Editorial Team
    • Frequently asked questions
    • Comments
    • Press Releases
    • Disclaimer
  • Subscribe
  • Contact

Diabetes News

Tag: GLP1


Real-world clinical outcomes following treatment intensification with GLP-1 RA, OADs or insulin in patients with type 2 diabetes on two oral agents (PATHWAY 2-OADs)

January 11th 2021

In propensity score-matched cohorts, GLP-1 RAs demonstrated significant benefits for both glycemic control and weight management over additional OAD(s) or insulin, respectively, indicating that they may represent the optimal choice at these points in the treatment pathway (BMJ Open, Diabetes Research & Care)

Categories: Medication, News
Tags: GLP1, Type 2 Diabetes

Categories: Medication
Tags: GLP1, Type 2 Diabetes

Potential unrealized mortality benefit of glucagon‐like peptide‐1 receptor agonists and sodium‐glucose co‐transport‐2 inhibitors

December 16th 2020

This analysis indicates unrealized opportunities to reduce mortality in selected veterans with T2D and CAD via increased GLP‐1RA and SGLT2i use (Diabetes, Obesity and Metabolism)

Categories: Medication, News
Tags: GLP1, SGLT2 inhibitors

Categories: Medication
Tags: GLP1, SGLT2 inhibitors

Diabetes medications with cardiovascular protection as we enter a new decade

June 10th 2020

Can SGLT2 inhibitors, long-acting GLP-1 receptor agonists, pioglitazone and metformin complement each other to save lives? (ABCD)

Categories: Medication, News
Tags: GLP1, metformin, pioglitazone, SGLT2 inhibitors

Categories: Medication
Tags: GLP1, metformin, pioglitazone, SGLT2 inhibitors

Glycemic efficacy and safety of glucagon-like peptide-1 receptor agonist on top of sodium-glucose co-transporter-2 inhibitor treatment compared to sodium-glucose co-transporter-2 inhibitor alone: a systematic review and meta-analysis of randomized controlled trials

November 14th 2019

This meta-analysis suggests that a GLP-1RA/SGLT-2i combination, if tolerated, exerts significant beneficial effects on glycemic control and body weight loss, however increasing the risk for any hypoglycemia and gastrointestinal adverse event (Diabetes Research and Clinical Practice)

Categories: Medication, News
Tags: GLP1, GLP1 receptor agonist, SGLT2 inhibitors

Categories: Medication
Tags: GLP1, GLP1 receptor agonist, SGLT2 inhibitors

Greater glucagon-like peptide-1 responses to oral glucose are associated with lower central and peripheral blood pressures

October 7th 2019

Greater glucose-stimulated GLP-1 responses were associated with clinically relevant lower central and peripheral blood pressures, consistent with beneficial effects on the cardiovascular system and reduced risk of CVD and mortality (Cardiovascular Diabetology)

Categories: Hypertension, News
Tags: GLP1

Categories: Hypertension
Tags: GLP1

The future of new drugs for diabetes management

July 19th 2019

The future of the newer classes of glucose-lowering drugs, namely dipeptidyl peptidase-4 (DPP-4) inhibitors, glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium/glucose co-transporter-2 (SGLT-2) inhibitors, is being redefined by the large prospective cardiovascular outcome trials (Diabetes Research and Clinical Practice)

Categories: Medication, News
Tags: DPP4, GLP1, SGLT2 inhibitors

Categories: Medication
Tags: DPP4, GLP1, SGLT2 inhibitors

A randomized trial comparing the efficacy and safety of treating patients with very elevated hba1c levels with basal‐bolus insulin or a glp‐1 receptor agonist plus basal insulin

May 31st 2019

In patients with HbA1c≥10% treatment with GLP1RA plus basal insulin, compared with basal‐bolus insulin, resulted in better glycemic control and weight, lower insulin dosage and hypoglycemia, and improved quality of life. This treatment strategy is an effective and safe alternative to basal‐bolus insulin regimen (Diabetes, Obesity and Metabolism)

Categories: Management, News
Tags: GLP1, insulin

Categories: Management
Tags: GLP1, insulin

Incretin-Based Antihyperglycemic Agents for the Management of Acute Ischemic Stroke in Patients with Diabetes Mellitus: A Review

February 6th 2019

Several preclinical studies consistently showed that GLP-1 receptor agonists reduce infarct volume and improve the functional outcome after ischemic stroke. These beneficial effects appear to be mediated by anti-inflammatory, antioxidant, and anti-apoptotic actions of these agents (Diabetes Therapy)

Categories: News, Treatment
Tags: GLP1, stroke

Categories: Treatment
Tags: GLP1, stroke

Fracture Risk After Initiation of Use of Canagliflozin: A Cohort Study

January 2nd 2019

In this study of middle-aged patients with type 2 diabetes and relatively low fracture risk, canagliflozin was not associated with increased risk for fracture compared with GLP-1 agonists (Annals of Internal Medicine)

Categories: Medication, News
Tags: canagliflozin, GLP1, Type 2 Diabetes

Categories: Medication
Tags: canagliflozin, GLP1, Type 2 Diabetes

Insulin and glucose‐lowering agents for treating people with diabetes and chronic kidney disease

November 1st 2018

Evidence concerning the efficacy and safety of glucose‐lowering agents for people with diabetes and CKD is limited. SGLT2 inhibitors and GLP‐1 agonists are probably efficacious for lowering glucose levels. Other potential effects of SGLT2 inhibitors include lower BP, lower potassium levels and a reduced risk of heart failure but an increased risk of genital infections. The safety of GLP‐1 agonists is uncertain (Cochrane Library)

Categories: Medication, News
Tags: CKD, GLP1, SGLT2 inhibitors

Categories: Medication
Tags: CKD, GLP1, SGLT2 inhibitors

Glucagon-like peptide-1 analogue liraglutide facilitates wound healing by activating PI3K/Akt pathway in keratinocytes

October 24th 2018

Our study suggests that liraglutide may be a potential target drug to improve skin ulcer with diabetes through its specific receptor GLP-1 (Diabetes Research and Clinical Practice)

Categories: News, Wound Care
Tags: GLP1

Categories: Wound Care
Tags: GLP1

Combination Therapy with GLP-1 Receptor Agonists and SGLT-2 Inhibitors in Older Patients with Type 2 Diabetes: a Real-World Evidence Study

September 9th 2018

This study’s findings provide evidence of clinically-meaningful reductions in HbA1c, body weight, and SBP in older T2D patients on combined regimens. The dropout and hypoglycemia rate were minimal and treatment was tolerated well (Canadian Journal of Diabetes)

Categories: Medication, News
Tags: GLP1, SGLT2 inhibitors, Type 2 Diabetes

Categories: Medication
Tags: GLP1, SGLT2 inhibitors, Type 2 Diabetes

Cardiovascular outcome studies in type 2 diabetes : comparison between SGLT2 inhibitors and GLP-1 receptor agonists

June 24th 2018

Currently, there is a paradigm shift in T2DM management, moving from a primary objective of glucose control to a cardiovascular and renal protection (Diabetes Research and Clinical Practice)

Categories: Medication, News
Tags: GLP1, SGLT2 inhibitors

Categories: Medication
Tags: GLP1, SGLT2 inhibitors

The effect of glucagon-like peptide 1 and glucagon-like peptide 1 receptor agonists on energy expenditure

May 30th 2018

This review indicates that GLP-1 has no short-term effect on REE but may decrease DIT. The GLP-1RA exenatide and liraglutide had a neutral effect on REE, although it was not possible to rule out an increase in REE following prolonged treatment (Diabetes Research and Clinical Practice)

Categories: Medication, News
Tags: exenatide, GLP1, liraglutide

Categories: Medication
Tags: exenatide, GLP1, liraglutide

Treatment Intensification in Type 2 Diabetes: A Real-World Study of 2-OAD Regimens, GLP-1 RAs, or Basal Insulin

April 25th 2018

Despite robust HbA1c lowering following treatment initiation, many patients did not achieve HbA1c < 7.0%. Basal insulin, generally prescribed for patients with high baseline HbA1c, was associated with a large reduction in HbA1c and with higher costs. Therapy intensification at an appropriate time could lead to clinical and economic benefits and should be investigated further (Diabetes Therapy)

Categories: Management, News
Tags: GLP1, insulin, Type 2 Diabetes

Categories: Management
Tags: GLP1, insulin, Type 2 Diabetes

Association Between Use of Sodium-Glucose Cotransporter 2 Inhibitors, Glucagon-like Peptide 1 Agonists, and Dipeptidyl Peptidase 4 Inhibitors With All-Cause Mortality in Patients With Type 2 Diabetes

April 18th 2018

In patients with type 2 diabetes, the use of SGLT-2 inhibitors or GLP-1 agonists was associated with better mortality outcomes than DPP-4 inhibitors (JAMA)

Categories: Medication, News
Tags: DPP4, GLP1, SGLT2 inhibitors, Type 2 Diabetes

Categories: Medication
Tags: DPP4, GLP1, SGLT2 inhibitors, Type 2 Diabetes

Insulin/Glucagon-Like Peptide-1 Receptor Agonist Combination Therapy for the Treatment of Type 2 Diabetes: Are Two Agents Better Than One?

April 16th 2018

We consider the benefits and limitations of these medications based on data from randomized clinical trials and discuss how they may address barriers to treatment intensification  (Clinical Diabetes)

Categories: News, Treatment
Tags: GLP1, insulin, Type 2 Diabetes

Categories: Treatment
Tags: GLP1, insulin, Type 2 Diabetes

Combination of basal insulin and GLP-1 receptor agonist: is this the end of basal insulin alone in the treatment of type 2 diabetes?

April 3rd 2018

This article reviews the efficacy and safety of different strategies to initiate and intensify basal insulin, with focus on new fixed ratio combinations of basal insulin with GLP-1 RAs available for use in a single injection pen (insulin degludec/liraglutide and insulin glargine/lixisenatide) (Diabetology & Metabolic Syndrome)

Categories: Medication, News
Tags: GLP1, insulin, Type 2 Diabetes

Categories: Medication
Tags: GLP1, insulin, Type 2 Diabetes

Contrasting effects on the risk of macrovascular and microvascular events associated with anti-hyperglycaemic drugs that enhance sodium excretion and lower blood pressure

March 13th 2018

Three classes of anti-hyperglycaemic medications are distinguished by their urinary sodium excretion-enhancing and blood pressure-lowering actions: long-acting glucagon-like peptide-1 receptor agonists, dipeptidyl peptidase-4 inhibitors and sodium-glucose co-transporter-2 inhibitors (Diabetic Medicine)

Categories: Medication, News
Tags: DPP4, GLP1, SGLT2 inhibitors

Categories: Medication
Tags: DPP4, GLP1, SGLT2 inhibitors

Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis

January 29th 2018

Our findings show cardiovascular safety across all GLP-1 receptor agonist cardiovascular outcome trials and suggest that drugs in this class can reduce three-point major adverse cardiovascular events, cardiovascular mortality, and all-cause mortality risk, albeit to varying degrees for individual drugs, without significant safety concerns (The Lancet Diabetes & Endocrinology)

Categories: Cardiovascular, News
Tags: GLP1, Type 2 Diabetes

Categories: Cardiovascular
Tags: GLP1, Type 2 Diabetes
  • 1
  • 2
  • 3
  • Next Page »

Subscribe

subscribe-iconFREE weekly updates by email Please CLICK HERE

Platinum Sponsors

Boehringer Ingelheim Lilly

Gold Sponsors

Novo NordiskAstraZenecaSanofi DiabetesNapp Diabetes

Silver Sponsors

Welsh Endocrinology and Diabetes Society (WEDS)AmgenAbbott Diabetes Care

FUNDING NOTICE

The Glycosmedia website and newsletter has been made possible with funding support from our sponsors. None of our sponsors have control over the content of the website, newsletter, apps, Twitter feed or RSS newsfeed.

For information about sponsorship and advertising please contact our editor-in-chief Jim Young jim@glycosmedia.com

Advertisers

CRC Press

The organisations advertising in this section do not have any input into, or editorial control over the content of this website.

Categories

  • Audits
  • Bariatric
  • Biochemistry
  • Cardiovascular
  • Devices
  • Diagnosis
  • Diet
  • Education
  • Epidemiology
  • Genetics
  • Gestational
  • Guidance
  • Guidelines
  • Hepatology
  • Hypertension
  • Immunology
  • Management
  • Media
  • Medication
  • Meetings
  • Monitoring
  • Nephrology
  • Neuropathy
  • Nephropathy
  • Obesity
  • Ophthalmology
  • Paediatrics
  • Pathology
  • Pharma
  • Pharmacology
  • Physiology
  • Podiatry
  • Prediabetes
  • Prevalence
  • Prevention
  • Psychological
  • Reports
  • Research
  • Screening
  • Sponsorship
  • Technology
  • Testing
  • Transplantation
  • Treatment
  • Wound Care

To see all articles associated with a category just click on the category name.

Popular Tags

ADA BMI canagliflozin CGM CKD closed-loop COVID-19 dapagliflozin DPP4 Empagliflozin exenatide GLP1 glycaemic control HbA1c heart failure hyperglycemia hypoglycemia incretin insulin insulin pump Insulin resistance Ketoacidosis lada liraglutide metformin microvascular mortality NAFLD NICE pioglitazone pregnancy retinopathy semaglutide SGLT2 inhibitors sitagliptin statin sulfonylureas Type 1 Diabetes Type 2 Diabetes Vitamin D

To see all articles associated with a tag just click on the tag name.

Complete list of Tags ››

Join us on Facebook

Join us on Facebook

Please share Glycosmedia:

Follow us on Twitter

My Tweets

mobileGlycosmedia is also available as an App:

For iPhone and iPad | For Android devices


Sponsorship and Advertising

For information about sponsorship and advertising please contact our editor-in-chief Jim Young jim@glycosmedia.com

Copyright © 2021 Glycosmedia Partnership